• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

Qprotyn Inc

Wednesday, June 05, 2024
Company Presentation
Platform for Therapeutics
Company Presentation Theater 4
At Qprotyn our mission is to advance HILOPRO® - our unique and patented viscosity-reducing technology for antibodies which enables them to be injectable subcutaneously, without the use of hyaluronidase.   HILOPRO® viscosity-reduction technology will facilitate a formulation at a concentration greater than 250mg/mL at injectable viscosities < 20cP. This would enable 500mg+ doses in a standard 2cc syringe with a 27 gauge needle. Our platform technology works with mAbs and other protein biologics, using two common and safe excipients in combination, and was patented in 2020.
Qprotyn Inc
Company Website: http://www.qprotyn.com
Lead Product in Development: HILOPRO® viscosity-reduction technology for high-concentration mAbs enabliing them for subcutaneous delivery
Number Of Unlicensed Products (For Which You Are Seeking Partners): 3 Products for High-Concentration (>250mg/mL with viscosity <20cP) 1. Innovator Monoclonal Antibodies 2. High Concentration SC Biosimilars 3. SC Immunoglobulins

Company HQ City

Cambridge

Company HQ State

Massachusetts

Company HQ Country

United States

CEO/Top Company Official

Lynn Hartung - President, Qprotyn Inc.

Development Phase of Primary Product

Pre-Clinical
Primary Speaker
Janak Vadgama, MSc
Head of BD and Customer Experience
Qprotyn Inc
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS